Notably, two CLL patients (38) maintained 97%-99% of their CD4+ CAR-T cell population years after treatment, with these persistent CD4+ CAR-T cells retaining functional activity, continuous activation markers, and proliferative capacity. The gene discussed is CD4; the disease is B-cell chronic lymphocytic leukemia.